www.rsc.org/obc

## **Exploiting the palladium[0]-catalysed Ullmann cross-coupling reaction in natural products chemistry: application to a total synthesis of the alkaloid (±)-aspidospermidine**

## **Martin G. Banwell\* and David W. Lupton**

*Research School of Chemistry, Institute of Advanced Studies, The Australian National University, Canberra, ACT 0200, Australia. E-mail: mgb@rsc.anu.edu.au*

*Received 19th October 2004, Accepted 15th November 2004 First published as an Advance Article on the web 7th December 2004*

## **Azide 14, available through the title cross-coupling process, has been converted,** *via* **the ring-fused aziridine 15, into the alkaloid aspidospermidine.**

We have recently disclosed a two-step process for the perparation of indoles that involves the initial palladium[0] catalysed Ullmann cross-coupling of *o*-nitrohalobenzenes with readily available a-halo-enones or -enals.**<sup>1</sup>** The resulting a-(*o*nitrophenyl)enones or -enals then engage in a simple reductive cyclisation reaction to deliver the target indoles.**<sup>2</sup>** We are now seeking to exploit such chemistry in the development of a total synthesis of the structurally complex and clinically significant indole–indoline binary alkaloid vinblastine (**1**),**<sup>3</sup>** a compound that had eluded *de novo* total synthesis until recently.**<sup>4</sup>** As part of such endeavours, we have recently shown<sup>5</sup> that the micro-organism *Pseudomonas putida* BGXM1 can convert *m*ethyltoluene into the metabolite **2**, a compound incorporating key elements associated with the C-ring of compound **1**. Herein we outline complementary work that has culminated in the synthesis of the racemic modification of the alkaloid aspidospermidine (**3**),**<sup>6</sup>** a compound embodying the ABCDE-ring system associated with vinblastine. This study serves to highlight the synthetic utility of a-(*o*-nitrophenyl)enones available through the title cross-coupling process as well as the likelihood of being able to exploit compound **2** in developing a synthesis of vinblastine.



The synthesis of the  $\alpha$ -iodocyclohexenone required for the Pd[0]-catalysed Ullmann cross-coupling reaction is shown in Scheme 1. Thus, commercially available 3-ethoxycyclohexenone (**4**) was treated with ethylmagnesium bromide and the resulting tertiary-alcohol subjected to an acidic work-up. In this manner the previously reported enone **5<sup>7</sup>** was obtained in 89% yield. Subjection of the last compound to 1,2-reduction using sodium borohydride gave the expected allylic alcohol which was immediately acetylated under standard conditions to provide



**Scheme 1** *Reagents and conditions*: (i) EtMgBr (2 mol equiv.), THF, 18 *◦*C, 3 h then 10% aq. HCl, 0 *◦*C, 14 h; (ii) NaBH4 (1 mol equiv.), MeOH, 0→18 °C, 3 h; (iii) Ac<sub>2</sub>O (2 mol equiv.), DMAP (cat.), pyridine, 0→18 *◦*C, 10 h; (iv) LDA (1.2 mol equiv.), TBDMS–Cl (1.3 mol equiv.), THF, −78→66 *◦*C, 6 h then MeOH, 18 *◦*C, 14 h; (v) LiAlH4 (7 mol equiv.), THF, 0→18 <sup>°</sup>C, 4 h; (vi) TEMPO (cat.), PhI(OAc)<sub>2</sub> (1.1 mol equiv.), CH<sub>2</sub>Cl<sub>2</sub>, 18 °C, 5 h; (vii) Ph<sub>3</sub>P=C(H)OMe (1.1 mol equiv.), THF, −78→18 *◦*C, 3 h; (viii) 1 : 10 v/v 10% aq. HCl–THF, 0 *◦*C, 3 h; (ix) NaBH4 (1 mol equiv.), MeOH, 0→18 *◦*C, 3 h; (x) Ac2O (2 mol equiv.), DMAP (cat.), pyridine,  $0 \rightarrow 18$  °C, 10 h; (xi) Cr(CO)<sub>6</sub> (0.5 mol equiv.), 70% *t*-BuOOH (3.0 mol equiv.), MeCN, 82 °C, 14 h; (xii) I<sub>2</sub> (4 mol equiv.), 1 : 1 v/v CCl4–pyridine, 18 *◦*C, 12 h.

the allylic acetate **6<sup>8</sup>** in 96% yield over the two steps. The ketene acetal obtained by treating compound **6** with LDA then *tert*-butyldimethylsilyl chloride (TBDMS–Cl) engaged in an Ireland–Claisen rearrangement**<sup>9</sup>** reaction on heating in refluxing THF and, after workup, the cyclohexene acetic acid **7<sup>10</sup>** was obtained (62%). Acid **7** was reduced to the corresponding alcohol **8<sup>11</sup>** (96%) using lithium aluminium hydride (LAH) and the latter then oxidised to the corresponding aldehyde using the protocol of Margarita *et al*. **<sup>12</sup>** Reaction of this aldehyde with (methoxymethylene)triphenylphosphorane, generated *in situ* by treating the corresponding phosphonium salt with sodium hexamethyldisilazide, afforded a 1 : 1 mixture of the *E*- and *Z*-isomers of the alkenyl ether **9** in 92% over these two steps.

Acid-catalysed hydrolysis of the last compound and reduction of the resulting aldehyde with sodium borohydride then afforded the higher homologue, **10** (84% from **9**), of alcohol **8**. The readily derived acetate was then subjected to allylic oxidation using  $Cr(CO)<sub>6</sub>-t-BuOOH<sup>13</sup>$  to give enone 11 (65% from 10). Subjection of compound  $11$  to the versatile  $\alpha$ -iodination protocol of Johnson and coworkers**<sup>14</sup>** finally gave the target halide **12** in quantitative yield.

The initial step associated with the second stage (Scheme 2) of our synthesis of aspidospermidine involved the pivotal Pd[0] catalysed Ullmann cross-coupling of a-iodoenone **12** with *o*iodonitrobenzene. This was achieved in DMSO at 70 *◦*C using 5 g atom equiv. of copper powder and  $Pd_2(dba)$  as catalyst. In this manner compound **13** was obtained in 75% yield. In anticipation of carrying out an intramolecular 1,3-dipolar cycloaddition reaction of the type recently reported by Guo and Schultz,**<sup>15</sup>** acetate **13** was hydrolysed to the corresponding alcohol and the readily derived mesylate reacted with sodium azide in DMF at 67 *◦*C to give compound **14** in 87% yield over these three steps. Heating a benzene solution of azide **14** at *ca.* 75 *◦*C for three days then afforded the ring-fused aziridine **15** in 72% yield. The triazoline arising from 1,3-dipolar cycloaddition of the azide moiety within substrate **14** to the tethered  $\alpha$ -( $o$ -nitroaryl)enone unit is undoubtedly the immediate precursor to product **15** although it could not be isolated from the reaction mixture.**<sup>16</sup>** After much experimentation we established that regioselective cleavage of aziridine **15** could be achieved by treating this compound with an ethereal solution of HCl in CH<sub>2</sub>Cl<sub>2</sub>. The resulting and rather unstable hydrochloride salt of a-chloroketone **16**, which was obtained as a single diastereoisomer, was immediately subjected to reduction with titanium trichloride·3THF in the presence of ammonium acetate. In this manner the crystalline indole **17** (mp 172–177 *◦*C; lit.**<sup>6</sup>***<sup>g</sup>* mp 180–182 *◦*C) was obtained in 46% yield over the two steps. The physical and spectral data derived



**Scheme 2** *Reagents and conditions*: (i) *o*-nitroiodobenzene (2 mol equiv.), Cu (5 g atom equiv.), Pd<sub>2</sub>(dba)<sub>3</sub> (cat.), DMSO, 70  $\degree$ C, 5 h; (ii) 1 : 4 v/v 1 M aq. K2CO3–MeOH, 18 *◦*C, 16 h; (iii) MsCl (1.2 mol equiv.), Et<sub>3</sub>N (1.2 mol equiv.), Et<sub>2</sub>O,  $0 \rightarrow 18 °C$ , 2 h; (iv) NaN<sub>3</sub> (3 mol equiv.), DMF, 67 °C, 3 h; (v) C<sub>6</sub>H<sub>6</sub>, 75 °C, 3 d; (vi) 1 M HCl in Et<sub>2</sub>O (2.4 mol equiv.), CH<sub>2</sub>Cl<sub>2</sub>,  $-15°$ C, 1.5 h; (vii) TiCl<sub>3</sub>·3THF (10 mol equiv.) in 1 : 2 : 2 v/v/v H2O–2.5 M aq. NH4OAc–acetone, 18 *◦*C, 0.33 h.

from this material proved a good match, in all respects, with those reported previously by Wenkert and Hudlicky**<sup>6</sup>***<sup>g</sup>* who have described a two-step method for the conversion of compound **17** into aspidospermidine (**3**). However, we followed the slightly longer but higher yielding procedure (Scheme 3) described by Toczko and Heathcock**<sup>6</sup>***<sup>r</sup>* in completing the present synthesis of  $(\pm)$ -aspidospermidine. Thus, reaction of piperidine 17 with  $\alpha$ chloroacetyl chloride afforded the a-chloroamide **18<sup>6</sup>***<sup>r</sup>* (69%) that was, in turn, converted into the corresponding a-iodoamide **19<sup>6</sup>***<sup>r</sup>* under Finkelstein conditions. Treatment of this last compound with silver(I) triflate then gave the lactam  $20<sup>6</sup>r$  which was reduced with LAH to give  $(\pm)$ -aspidospermidine (3) (47% yield from amide **18**). The spectral data derived from this material matched those reported**<sup>6</sup>***n,<sup>r</sup>* for the natural product.



**Scheme 3** *Reagents and conditions*: (i) a-chloroacetyl chloride (1.1 mol equiv.), Et<sub>3</sub>N (1.1 mol equiv.), CH<sub>2</sub>Cl<sub>2</sub>, 0→18 °C, 2 h; (ii) NaI (10 mol equiv.), acetone, 56 *◦*C, 2 h; (iii) AgOTf (2 mol equiv.), THF, 18 *◦*C, 0.5 h; (iv) LAH (4 mol equiv.), THF, 18→66 *◦*C, 2 h.

The *S*-enantiomer of compound **8** is readily available**<sup>11</sup>** in 96% ee so the present work also constitutes a formal total synthesis of the unnatural or (−)-enantiomer of aspidospermidine. Since *R*-**8** will almost certainly be available by closely related means, the chemistry presented here should also allow access to the naturally occurring enantiomeric forms of various *Aspidosperma* alkaloids.

## **Notes and references**

- 1 M. G. Banwell, B. D. Kelly, O. J. Kokas and D. W. Lupton, *Org. Lett.*, 2003, **5**, 2497.
- $2$  Analogous protocols utilising  $\beta$ -halo-enones or -enals have been applied to the preparation of quinolines; M. G. Banwell, D. W. Lupton, X. Ma, J. Renner and M. O. Sydnes, *Org. Lett.*, 2004, **6**, 2741.
- 3 Antitumor Bisindole Alkaloids from *Catharanthus roseus* (L.), *The Alkaloids, Vol. 37*, ed. A. Brossi and M. Suffness, Academic Press, San Diego, CA, 1990.
- 4 (*a*) S. Yokoshima, T. Ueda, S. Kobayashi, A. Sato, T. Kuboyama, H. Tokuyama and T. Fukuyama, *J. Am. Chem. Soc.*, 2002, **124**, 2137; for useful reviews see; (*b*) S. Yokoshima, T. Ueda, S. Kobayashi, A. Sato, T. Kuboyama, H. Tokuyama and T. Fukuyama, *Pure Appl. Chem.*, 2003, **75**, 29; (*c*) C. Schneider, *Angew. Chem., Int. Ed.*, 2002, **41**, 4217.
- 5 M. G. Banwell, A. J. Edwards, D. W. Lupton and G. Whited, *Aust. J. Chem.*, in press.
- 6 For previously reported total syntheses of aspidospermidine see; (*a*) G. Stork and J. E. Dolfini, *J. Am. Chem. Soc.*, 1963, **85**, 2872; (*b*) A. Camerman, N. Camerman, J. P. Kutney, E. Piers and J. Trotter, *Tetrahedron Lett.*, 1965, 637; (*c*) J. Harley-Mason and M. Kaplan, *J. Chem. Soc., Chem. Commun.*, 1967, 915; (*d*) J.-Y. Laronze, J. Laronze-Fontaine, J. Lévy and J. Le Men, *Tetrahedron Lett.*, 1974, 491; (*e*) Y. Ban, K. Yoshida, J. Goto and T. Oishi, *J. Am. Chem. Soc.*,

1981, **103**, 6990; (*f*) T. Gallagher, P. Magnus and J. Huffman, *J. Am. Chem. Soc.*, 1982, **104**, 1140; (*g*) E. Wenkert and T. Hudlicky, *J. Org. Chem.*, 1988, **53**, 1953; (*h*) S. B. Mandal, V. S. Giri, M. S. Sabeena and S. C. Pakrashi, *J. Org. Chem.*, 1988, **53**, 4236; (*i*) A. I. Myers and D. Berney, *J. Org. Chem.*, 1989, **54**, 4673; (*j*) M. Node, H. Nagasawa and K. Fuji, *J. Org. Chem.*, 1990, **55**, 517; (*k*) P. Le Menez, N. Kunesch, S. Liu and E. Wenkert, *J. Org. Chem.*, 1991, **56**, 2915; (*l*) D. Desmaele and J. d'Angelo, *J. Org. Chem.*, 1994, **59**, 2292; (*m*) E. Wenkert and S. Liu, *J. Org. Chem.*, 1994, **59**, 7677; (*n*) P. Forns, A. Diez and M. Rubiralta, *J. Org. Chem.*, 1996, **61**, 7882; (*o*) A. G. Schultz and L. Pettus, *J. Org. Chem.*, 1997, **62**, 6855; (*p*) O. Callaghan, C. Lampard, A. R. Kennedy and J. A. Murphy, *J. Chem. Soc., Perkin Trans. 1*, 1999, 995; (*q*) R. Iyengar, K. Schildknegt and J. Aube,´ *Org. Lett.*, 2000, **2**, 1625; (*r*) M. A. Toczko and C. H. Heathcock, *J. Org. Chem.*, 2000, **65**, 2642; (*s*) B. Patro and J. A. Murphy, *Org. Lett.*, 2000, **2**, 3599; (*t*) S. A. Kozmin, T. Iwama, Y. Huang and V. H. Rawal, *J. Am. Chem. Soc.*, 2002, **124**, 4628; (*u*) M. G. Banwell and J. A. Smith, *J. Chem. Soc., Perkin Trans. 1*, 2002, 2613; (*v*) J. P. Marino, M. B. Rubio, G. Cao and A. de Dios, *J. Am. Chem. Soc.*, 2002, **124**, 13398; (w) D. Gnecco, E. Vázquez, A. Galindo, J. L. Terán, L. Orea, S. Bernès and R. G. Enríquez, *ARKIVOC*, 2003, **xi**, 185; (*x*) H. Tanino, K. Fukuishi, M. Ushiyama and K. Okada, *Tetrahedron*, 2004, **60**, 3273.

- 7 B.-D. Chong, Y.-I. Ji, S.-S. Oh, J.-D. Yang, W. Bank and S. Koo, *J. Org. Chem.*, 1997, **62**, 9323 and references cited therein.
- 8 M. Hirano and T. Morimoto, *J. Chem. Soc., Perkin Trans. 2*, 1985, 1105.
- 9 (*a*) S. R. Schow, J. D. Bloom, A. S. Thompson, K. N. Winzenberg and A. B. Smith III, *J. Am. Chem. Soc.*, 1986, **108**, 2662; (*b*) P. Wipf, in *Comprehensive Organic Synthesis*, ed. B. M. Trost and I. Fleming, Pergamon Press, Oxford, 1991, vol. 5, pp. 840–847.
- 10 Y. Simoji, F. Saito, K. Tomita and Y. Morisawa, *Heterocycles*, 1991, **32**, 2389.
- 11 The *S*-enantiomer of compound **8** is known: G. Palmisano, P. D'Anniballe and M. Santagostino, *Tetrahedron*, 1994, **50**, 9487.
- 12 A. De Mico, R. Margarita, L. Parlanti, A. Vescovi and G. Piancatelli, *J. Org. Chem.*, 1997, **62**, 6974.
- 13 A. J. Pearson, Y.-S. Chen, G. R. Han, S.-Y. Hsu and T. Ray, *J. Chem. Soc., Perkin Trans. 1*, 1985, 267.
- 14 C. R. Johnson, J. P. Adams, M. P. Braun, C. B. W. Senanayake, P. M. Wovkulich and M. R. Uskokovic, *Tetrahedron Lett.*, 1992, **33**, 917.
- 15 Z. Guo and A. G. Schultz, *Tetrahedron Lett.*, 2004, **45**, 919.
- 16 The triazoline derived from thermolysis of the des-ethyl analogue of compound **14** is an isolable and crystalline species that has been characterised by single-crystal X-ray analysis. Full details will be reported in due course.